Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.